Please use this identifier to cite or link to this item:
Title: 30-day valve in valve transcatheter aortic valve implantation outcomes, from ACE-TAVI registry.
Epworth Authors: Haji, Kawa
Nanayakkara, Shane
Palmer, Sonny
Noaman, Samer
Dick, Ronald
Walton, Antony
Other Authors: Zimmet, Adam
McGaw, David
Reid, J
Johnston, Rox
Htun, Nay Min
Stub, Dion
Keywords: Valve in Valve Transcatheter Aortic Valve Implantation
Bioprosthetic Valve Failure
Clinical Outcome
ACE-TAVI Registry
Cardiac Sciences Clinical Institute
Issue Date: Oct-2023
Conference Name: Epworth HealthCare Research Month 2023
Conference Location: Epworth Research Institute, Victoria, Australia
Abstract: There is an increasing number of surgical and transcatheter bioprosthetic valve implantations which after a few years eventually fail. Analysis of data was undertaken from ACE-TAVI registry, a prospective TAVI registry that incudes 3 major hospitals in Melbourne, Victoria. All patients who underwent VIV TAVI from 2008 to 2022 were included. Data from a large Australian multicentre registry shows that similar to overseas, VIV TAVI is a safe procedure with excellent outcomes and favourable survival at 30 days
Type: Conference Poster
Affiliated Organisations: Alfred Health, Department of Cardiology, Melbourne, Victoria, Australia.
Cabrini, Malvern, Victoria, Australia
Type of Clinical Study or Trial: Retrospective studies
Appears in Collections:Research Month

Files in This Item:
File Description SizeFormat  
Valve in Valve_Kawa Haji.pdf427.31 kBAdobe PDFThumbnail

Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.